Glucagon-like peptide-1 (GLP-1) receptor agonists and other anti-obesity pharmacotherapies are widely acknowledged as supplementary alternatives for weight management in women with polycystic ovarian syndrome (PCOS) when lifestyle modifications prove inadequate. Here, GCG is linked to obesity disorder.